IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applicant:

Lior GEPSTEIN et al

Serial No.:

10/759,734

Filed:

January 20, 2004

For:

Methods Of Generating Human Cardiac Cells And Tissues

And Uses Thereof

Examiner:

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 MAY 0 4 2005 A

Group Art Unit: 1632

Attorney

Docket: 27395

INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,

Sol Sheinbein

Registration No. 25,457

Dated: May 2, 2005

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE sens are required on espond to a collection of information unless it contains a valid OMB control number.

Complete if Known Under the Paperwork Reduction Act of 1995, no pe Complete if Known Substitute for form 1449A/PTC Application Number 10/759,734

INFORMATION DISCLOSURE Filing Date January 20, 2004 STATEMENT BY APPLICANT First Named Inventor **GEPSTEIN** Lior et al Art Unit 1632 (use as many sheets as necessary) Examiner Name Attorney Docket Number Sheet 1 of 2 27395 U.S. PATENT DOCUMENTS Publication Date MM-DD-YYYY Pages, Columns, Lines, Where Examiner Cite Document Number Name of Patentee or Applicant of Cited Document Relevant Passages or Relevant Initials* No. Figures Appear Number-Kind Code^{2 (if known)} US-6,369,821 09-9-2002 Merril et al. 2 US-2002/0061587 05-23-2002 Anversa

		FOREIGN	PATENT DOC	UMENTS			
Examiner Initials*	Cite No. ¹	Foreign Patent Documents Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T 6
	3	PCT WO 03/008535	01-30-2003	Gepstein	et al.		
	4	PCT WO 01/62899	08-30-2001	Thomson et al.			
							<u> </u>
Examiner Signature					Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450



PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE formation unless it contains a valid OMB control number. Under the Panerwork Reduction Act of 1995, no.

Under the Paperw	ork Reduction	n Act of 1995, no persons are required to a collection of information un	Complete					
	Su	bstitute for form 1449A/PTO	Application Number 10/759,734					
	TRITE	ODMATION DISCLOSUDE	Filing Date	January 20, 2004				
		ORMATION DISCLOSURE	First Named Inventor	GEPSTEIN Lior e				
	STA	TEMENT BY APPLICANT	Group Art Unit	1632				
			Examiner Name					
		(use as many sheets as necessary)						
Sheet	2	Of 2	Attorney Docket Number	27395				
		OTHER PRIOR ART – NON PATENT LITER						
Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the						
Initials	No.1	item (book, magazine, journal, serial symposium, catalog, etc.) da publisher, city and/or country where p Itskovitz-Eldor et al. "Differentiation Of Human Emry	ublished.	1				
	5							
	Bodies Comprising the Three Embryonic Germ Layers", Molecular Medicine, 6(2):							
		88-95. 2000. Esp. P. 92-93.						
	6	Heschler et al. "EstablishmentOf Ionic Channels AndS	ignalling Cascades In Th	e				
		Embryonic Stem-Cell Derived Primitive Ectoderm And Cardiovascular System".						
		Cells Tissues and Organs, 165(3-4): 153-164, 1999.	-					
	7	Robbins et al. "Embryonic Stem Cells as A Model for	Cardiogenesis", Trends in	1				
		Cardiovascular Medicine, 2(2): 44-50, 1992.						
	8	Kehat et al. Long Term High-Resolution, Electrophys	iological Assessment Of					
	"	Human Embryonic Stem Cell Derived Cardiomyocytes		el For				
		The Human Heart", Circulation, 1023(18, Suppl.II): 2-		77.01				
	9	Baldwin et al. "Advances In Understanding The Molec		ac				
	"			ac				
	10	Development", Current Opinion in Pediatrics, 11: 413-418, 1999. Sanchez et al. "Iyosin Heavy Chain Gene Expression In Mouse Embryoid Bodies",						
	10							
	1	Journal of Biological Chemistry, 266,(23): 22419-22426, 1991.						
	11	Schuldiner et al. "Effects of Eight Growth Factors on the Differentiation of Cells Derived From Human Embryonic Stem Cells", PNAS, 97(21): 11307-11312, 2000.						
								
	12	Maltsev et al. "Cardiomyocytes Diffentiated In In Vitro From Embryonic Stem Cells						
		Developmentally Express Cardiac-Specific Genes And Research,: 233-244, 1994.	I Ionic Currents", Circicul	lar				
	13	Metzger et al. "Myosin Heavy Chain Expression in Co	ntracting Myocytesw Isol	lated				
		During Embryonic Stem Cell Cardiogenesis", Circular						
	14	Klug et al. "Genetically Selected Cardiomyocytes From						
	* '	Stem Cells Form Stable Intracardiac Grafts", Journal o						
		216-224, 1996.	. Ceur III. euriganien,	/ () /				
	15	Kehat et al. "Human Embryonic Stem Cells Can Differ	rentiate Into Myocytes W	ith				
	13	Structural And Functional Properties Of Cardiomyocyt	tes" The Journal of Clinic	cal				
		Investigations, 108(3): 407-414, 2001.	ies, the Journal of Chin	Cai				
		111vestigations, 100(3), 407-414, 2001.						
	+							
		-						
	+							

Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional).

2. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.